Coherus Oncology (CHRS) Income from Non-Controlling Interests (2014 - 2018)
Coherus Oncology (CHRS) reported Income from Non-Controlling Interests of -$18000.0 for Q3 2018, down 350.0% on a YoY basis from $7200.0 in Q3 2017, and up 61.7% sequentially from -$47000.0 in Q2 2018.
Coherus Oncology (CHRS) Income from Non-Controlling Interests (2014 - 2018) Analysis & Trends
Coherus Oncology (CHRS) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$18000.0 in Q3 2018.
- For the quarter ending Q3 2018, Income from Non-Controlling Interests fell 350.0% year-over-year to -$18000.0; the trailing twelve-month figure through Jun 2019 stood at -$18000.0 (down 131.03% YoY), and the FY2018 full-year result was -$70000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests advanced to -$18000.0 in Q3 2018, from -$47000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $155000.0 in Q4 2014 to a low of -$224000.0 in Q2 2015.
- A 5-year average of -$66611.1 and a median of -$56500.0 in 2017 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests surged 595.65% in 2017 and plunged 350.0% in 2018, its largest moves.
- Tracing CHRS's Income from Non-Controlling Interests over 5 years: stood at $155000.0 in 2014, then tumbled by 221.94% to -$189000.0 in 2015, then surged by 87.83% to -$23000.0 in 2016, then surged by 595.65% to $114000.0 in 2017, then tumbled by 115.79% to -$18000.0 in 2018.
- Business Quant data shows CHRS's Income from Non-Controlling Interests at -$18000.0 in Q3 2018, -$47000.0 in Q2 2018, and -$5000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -18,000.00 |
| Jun 30, 2018 | -47,000.00 |
| Mar 31, 2018 | -5,000.00 |
| Dec 31, 2017 | 114,000.00 |
| Sep 30, 2017 | -4,000.00 |
| Jun 30, 2017 | -66,000.00 |
| Mar 31, 2017 | -44,000.00 |
| Dec 31, 2016 | -23,000.00 |
| Sep 30, 2016 | -95,000.00 |
| Jun 30, 2016 | -183,000.00 |
| Mar 31, 2016 | -150,000.00 |
| Dec 31, 2015 | -189,000.00 |
| Sep 30, 2015 | -151,000.00 |
| Jun 30, 2015 | -224,000.00 |
| Mar 31, 2015 | -114,000.00 |
| Dec 31, 2014 | 155,000.00 |
| Sep 30, 2014 | -42,000.00 |
| Jun 30, 2014 | -113,000.00 |